Myriad Genetics (MYGN) Short term Debt (2016 - 2025)

Myriad Genetics (MYGN) reported Short term Debt of $59.4 million for Q2 2025, down 42.94% quarter-over-quarter from $104.1 million in Q2 2021.

Myriad Genetics (MYGN) Short term Debt (2016 - 2025) Analysis & Trends

Myriad Genetics (MYGN) has 7 years of Short term Debt data on file, last reported at $59.4 million in Q2 2025.

Short term Debt for Q2 2025 came in at $59.4 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $59.4 million (changed N/A YoY), and the FY2020 annual result was $3.1 million, down 8.82% from the prior year.
Short term Debt retreated to $59.4 million in Q2 2025 per MYGN's latest filing, from $104.1 million in the prior quarter.
Over five years, Short term Debt peaked at $104.1 million in Q2 2021 and troughed at $59.4 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	30,529.42 Bn	30,528.96 Bn	1.11 Bn
2	Thermo Fisher Scientific	183.75 Bn	180.50 Bn	7.74 Bn
3	Danaher	133.13 Bn	127.43 Bn	3.59 Bn
4	Idexx Laboratories	46.14 Bn	45.94 Bn	722.74 Mn
5	Agilent Technologies	38.20 Bn	36.39 Bn	990.00 Mn
6	Natera	31.50 Bn	30.40 Bn	696.04 Mn
7	Iqvia Holdings	31.34 Bn	29.36 Bn	1.36 Bn
8	Illumina	24.51 Bn	23.36 Bn	721.00 Mn
9	Mettler Toledo International	23.53 Bn	23.47 Bn	555.82 Mn
10	Myriad Genetics	424.93 Mn	300.53 Mn	137.60 Mn

Download Data